 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12...89101112131415161718...6970» |
- || ipatasertib (RG7440) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: IPATHER: Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients (clinicaltrials.gov) - Apr 18, 2023
P1, N=15, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
N=25 --> 15 | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Jun 2025
- | AST-301 / University of Washington, Aston Sci., EpiThany
Trial completion, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=31, Completed, Sponsor: University of Washington
N=25 --> 15 | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Jun 2025 Unknown status --> Completed
- ||| Perjeta (pertuzumab) / Roche
Clinical: 3cm at 49, I would be vary of deescalating just based on her2 dx. Not sure how much benefit you will get out of Pertuzumab but both anthra and non anthra chemo reasonable. Standard would be neoadjuvant. Gives a window of escalation if needed. (Twitter) - Apr 18, 2023
- | Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme, Perjeta (pertuzumab) / Roche
Journal: Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study. (Pubmed Central) - Apr 17, 2023
Unknown status --> Completed Combination of SC trastuzumab and intravenous pertuzumab for HER2-positive breast cancer is a safe and well-tolerated option in adjuvant setting.
- | Biomarker, Journal, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. (Pubmed Central) - Apr 17, 2023
P2
Cobimetinib plus atezolizumab had an unfavourable benefit:risk ratio in HER2?/MSS/BRAF mCRC. New strategies are required to increase the susceptibility of MSS mCRC to immunotherapy.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis. (Pubmed Central) - Apr 17, 2023
No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.
- ||| Perjeta (pertuzumab) / Roche
Clinical: Not really… the basic question is if you should give adjuvant treatment that do not prolong OS. Both PD1i and neoadj HER2 pertuzumab treatment were approved without OS data, but rather on surrogate endpoints… endpoints that now don’t seem to correlate that very well! (Twitter) - Apr 14, 2023
- || Review, Journal, IO biomarker: Emerging Targeted Therapies for HER2-Positive Breast Cancer. (Pubmed Central) - Apr 13, 2023
When patients progress to multiple strategies, there are several HER2-targeted therapies available; however, treatment options are limited, and the potential combination with other drugs, immune checkpoint inhibitors, CAR-T cells, CAR-NK, CAR-M, and vaccines is an interesting and appealing field that is still in development. In this review, we will discuss the highlights and pitfalls of the different HER2-targeted therapies and potential combinations to overcome metastatic disease and resistance to therapy.
- | Tukysa (tucatinib) / Pfizer, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: UCLA B-13: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (clinicaltrials.gov) - Apr 13, 2023
P1b, N=18, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
In this review, we will discuss the highlights and pitfalls of the different HER2-targeted therapies and potential combinations to overcome metastatic disease and resistance to therapy. Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024
- | imlunestrant (LY3484356) / Eli Lilly
Trial completion date, Combination therapy, Monotherapy, Metastases: EMBER: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (clinicaltrials.gov) - Apr 13, 2023
P1a/1b, N=500, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Dec 2023 --> Dec 2024
- | Herceptin (trastuzumab) / Roche, Imfinzi (durvalumab) / AstraZeneca, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (clinicaltrials.gov) - Apr 10, 2023
P2, N=39, Recruiting, Sponsor: The Methodist Hospital Research Institute
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Aug 2023 --> Feb 2025 | Trial primary completion date: Mar 2023 --> Sep 2024
- || Perjeta (pertuzumab) / Roche
It is an issue indeed, specially in places where early introduction of pertuzumab while using TCHP is not always achievable. Although, some trials of TCH showed some good pcr rates compared to Ac containing Regimen, still population of those studies were lower risk (Twitter) - Apr 9, 2023
- || Perjeta (pertuzumab) / Roche
Interesting! It is a very important issue, even more so in places where the use of pertuzumab is still complicated due to the cost of the medication.https://t.co/KD9yafcFLM. (Twitter) - Apr 9, 2023
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: In this case, after scans and no M1 disease, I would recommend TCHP. Here in Brazil, in the public setting, we also usually start with AC because of access to the trastuzumab/pertuzumab... (Twitter) - Apr 9, 2023
- ||| Perjeta (pertuzumab) / Roche
Clinical: Due to pertuzumab repayment conditions in our country, neoadjuvant therapy is usually started with AC. (Twitter) - Apr 9, 2023
- ||| GEJunction Adenocarcinoma:(fluorouracil [5-FU], leucovorin, oxaliplatin, and docetaxel [FLOT] chemotherapy versus FLOT plus trastuzumab and pertuzumab -no advantage of later (Twitter) - Apr 7, 2023
- || Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases: MyTACTIC: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (clinicaltrials.gov) - Apr 6, 2023
P2, N=252, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: Aug 2023 --> Feb 2025 | Trial primary completion date: Mar 2023 --> Sep 2024 Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2023
- |||||||||| BCD-178 (pertuzumab biosimilar) / Biocad
New P3 trial: PREFER: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta (clinicaltrials.gov) - Apr 6, 2023
P3, N=336, Recruiting, Sponsor: Biocad
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
HIGH HER2/CEP17 RATIO IS ASSOCIATED WITH BETTER TREATMENT OUTCOMES IN ADVANCED HER2-POSITIVE BREAST CANCER TREATED WITH PERTUZUMAB, TRASTUZUMAB, AND DOCETAXEL REGARDLESS OF HER2 2+ OR 3+ RESULTS () - Apr 4, 2023 - Abstract #GBCC2023GBCC_31;
In addition, this study identified the prognostic role of ISH even in patients with HER2 IHC 3+. ISH could be helpful even in patients with HER2 IHC 3+ to predict treatment outcome.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
ENHERTU, THE GAME CHANGER IN HER2+ MBC TREATMENT: FROM CLINICAL TRIAL TO CLINICAL PRACTICE (RM 1 (Vista 1+2)) - Apr 4, 2023 - Abstract #GBCC2023GBCC_21;
ISH could be helpful even in patients with HER2 IHC 3+ to predict treatment outcome. The HER2-positive metastatic breast cancer is majorly incurable disease despite the use of HER2- targeting agents, such as trastuzumab, pertuzumab, and lapatinib, because of frequent drug resistance, and patients eventually die from the breast cancer after several lines of systemic chemotherapy...In Destiny Breast02 trial, 608 HER2-positive metastatic breast cancer patients who were previously treated with T-DM1 received T-DXd (experimental) or treatment of physician
- Kadcyla (ado-trastuzumab emtansine) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Perjeta (pertuzumab) / Roche
SYSTEMIC TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER (RM 3 (Walker Hall 1)) - Apr 4, 2023 - Abstract #GBCC2023GBCC_13;
Extended therapy with neratinib could be considered for patients who have completed 1 year of trastuzumab when it is an ER+HER2+high risk disease. However, these suggestions should be discussed with patients considering the local reimbursement system, patients
- TARGETING HER2-LOW AND THE TREATMENT SEQUENCE (RM 1 (Vista 1+2)) - Apr 4, 2023 - Abstract #GBCC2023GBCC_7;
After a long journey, the HER2-directed therapy with trastuzumab deruxtecan finally crosses the boundary set for other anti-HER2 agents and establishes its efficacy in HER2-low breast cancer. In the near future, we may anticipate the development of strategies or drugs for patients with HER2-low breast cancer.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
All good points, Bijoy! Taking a step further, if we even buy into the neo-Adj benefit, how much is ongoing dual anti-her 2 therapy (addition of Pertuzumab) Vs single agent Trastuzumab post TCHP adding if you have achieved pCR? (Twitter) - Apr 4, 2023
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Preclinical, Journal: Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. (Pubmed Central) - Apr 4, 2023
Lastly, TVH intravenous administration to non-human primates was proven immunogenic and safe in a repeat-dose toxicity study. Nonclinical data presented here highlight TVH as a first-in-class immunotherapeutic vaccine platform currently under clinical investigation.
- | Observational data, Journal, Metastases: A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients. (Pubmed Central) - Apr 3, 2023
In this real-world study, we found that patients were treated with a wide variety of anti-cancer agents with modest efficacy. However, patients in this study did not have access to newer therapies like tucatinib and T-DXd.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Review, Journal: Targeting HER2 in colorectal cancer (Pubmed Central) - Mar 31, 2023
In this literature review, we present here the current state of knowledge on the diagnostic methods of HER2 overexpression in CRC, the main clinical, molecular and prognostic characteristics, and the efficacy results of the different therapeutic combinations for the patients with HER2 overexpressed mCRC. This justifies, despite the lack of marketing authorization in France and in Europe for agents targeting HER2 in CRC, the systematic evaluation of the HER2 status, as recommended in particular by the NCCN (National Comprehensive Cancer Network).
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal: Co-administration of pertuzumab and trastuzumab is practical in home hospitalization (Pubmed Central) - Mar 31, 2023
This justifies, despite the lack of marketing authorization in France and in Europe for agents targeting HER2 in CRC, the systematic evaluation of the HER2 status, as recommended in particular by the NCCN (National Comprehensive Cancer Network). No abstract available
- |||||| Piqray (alpelisib) / Novartis
Enrollment open, Enrollment change, Combination therapy, Metastases: EPIK-B2: Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (clinicaltrials.gov) - Mar 31, 2023
P3, N=511, Recruiting, Sponsor: Novartis Pharmaceuticals
No abstract available Active, not recruiting --> Recruiting | N=19 --> 511
- || imlunestrant (LY3484356) / Eli Lilly
Enrollment closed, Combination therapy, Monotherapy, Metastases: EMBER: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (clinicaltrials.gov) - Mar 29, 2023
P1a/1b, N=500, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting | N=19 --> 511 Recruiting --> Active, not recruiting
- | Perjeta (pertuzumab) / Roche
Journal: Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy. (Pubmed Central) - Mar 28, 2023
This novel immunotoxin has the potential to be applied as a therapeutic candidate for HER2-targeted cancer therapy. However further in vitro and in vivo evaluations are still required to confirm the efficacy and safety of this protein.
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2/3 trial, Combination therapy: DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (clinicaltrials.gov) - Mar 28, 2023
P2/3, N=30, Recruiting, Sponsor: Cancer Research UK
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Rapidly Developing Radiation Pneumonitis: A Case of Caution (Walter E. Washington Convention Center, Area E, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6231;
Radiation pneumonitis is considered a long-term sequelae of radiation therapy which manifests its true colors well after the completion of treatment. Rarely it may present early on during the treatment course upsetting the traditional cause-effect temporal association we have in our minds for it.
- |||| Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: Thanks for the comment, I was wondering if the patient had seen prior trastuzumab + pertuzumab. I wish your patient long durable remission but what has been your experience with tucatinib in HB / Upper GI tumors? (Twitter) - Mar 24, 2023
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical: In this particular case, we had a near path CR systemically and still NED to trastuzumab/pertuzumab; new disease on therapy noted only in brain. More of a drug penetration issue as opposed to true progression. Drugs penetrating the blood brain barrier still generating response.👇🏾 (Twitter) - Mar 24, 2023
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial completion date: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (clinicaltrials.gov) - Mar 24, 2023
P2, N=220, Recruiting, Sponsor: West German Study Group
Rarely it may present early on during the treatment course upsetting the traditional cause-effect temporal association we have in our minds for it. Unknown status --> Recruiting | Trial completion date: Aug 2020 --> Oct 2024
- || Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (clinicaltrials.gov) - Mar 24, 2023
P2, N=46, Completed, Sponsor: West German Study Group
Unknown status --> Recruiting | Trial completion date: Aug 2020 --> Oct 2024 Unknown status --> Completed | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Aug 2021 --> May 2022
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (clinicaltrials.gov) - Mar 23, 2023
P3, N=437, Active, not recruiting, Sponsor: The Netherlands Cancer Institute
Unknown status --> Completed | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Aug 2021 --> May 2022 Trial completion date: Dec 2024 --> Dec 2030
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
A retrospective review of patients receiving trastuzumab deruxtecan across five centres in Ireland with a subgroup analysis of patients with CNS involvement assessing response in the CNS (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_503;
Conclusions In this cohort the response rate of 44% is comparable to that seen in the DESTINY Breast01 subgroup analysis which showed a response rate of 58%. T-DXd continues to show a significant response rate in this important population of patients.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
The impact of initial tumor response to docetaxel, trastuzumab, and pertuzumab on survival outcomes of patients with HER2+ metastatic breast cancer: an exploratory analysis of the CLEOPATRA trial. (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_482;
P3
The outcome benefit of CR was equal in HR- and HR+ tumors, p=NS. Conclusions Obtaining an early radiological CR with D+T+P confers significantly longer OS and PFS, whereas no difference is observed once compared with PR and SD.
- Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_417;
P2
Two FFPE and one frozen sample are collected at (1) the time of enrollment and (2)following surgical treatment in those who undergo upfront surgery or dedicated biopsy after study treatment in those who undergo NST. Blood samples will be collected at the time of enrollment, before surgery or the start of NST, and at the end of the study visit.
- Ogivri (trastuzumab-dkst) / Biocon
Pathological complete response after neoadjuvant chemotherapy in Her2 positive breast cancer, efficacy of biosimilar compared to Herceptin (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_411;
Blood samples will be collected at the time of enrollment, before surgery or the start of NST, and at the end of the study visit. Two biosimilars are available at ower institution since 2017 (Hertraz
- Perjeta (pertuzumab) / Roche
Updated survival analysis in NEOPERSUR trial: Neoadjuvant Pertuzumab in a real-world population in the south of Spain. (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_407;
Background Pertuzumab (P) has been approved in neoadjuvant setting for HER2-positive early breast cancer patients (pts) in association with Trastuzumab (T) and chemotherapy...The majority of the patient received anthracyclines and taxanes with P and T regimen (77,1%), 16,5% received carboplatin-docetaxel-P-T combination and 6,5% received taxane-P-T...Conclusions In our knowledge, this is the first real-world study that shows survival results for adding Pertuzumab in the neoadjuvant setting of HER2-positive breast cancer patients. Our results are consistent with those previously published.
- Herceptin (trastuzumab) / Roche
Five-year survival analysis of phase II ZoNAnTax trial: Evaluation of Zoledronic-acid addition to a neoadjuvant Trastuzumab, Anthracycline and Docetaxel-containing regiment. (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_396;
P2
OS according to pCR status stratified by HR for HR- achieving pCR was 100% vs non-pCR 77.8% (p=0.23) and for HR+ achieving pCR was 94.1% vs non-pCR 80% (p=0.20). Conclusions Taken together with the safety and early efficacy, the long-term benefit of the ZoNAnTax regimen demonstrating DFS and OS rates as high as reported by pivotal studies that contained Pertuzumab in the same setting, suggests that adding ZOL as a repositioning drug to the NT of HER2+ BC should be considered.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Exploratory biomarker (BM) analyses from IMpassion050 (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_388;
P3
Conclusions Taken together with the safety and early efficacy, the long-term benefit of the ZoNAnTax regimen demonstrating DFS and OS rates as high as reported by pivotal studies that contained Pertuzumab in the same setting, suggests that adding ZOL as a repositioning drug to the NT of HER2+ BC should be considered. Background In IMpassion050 (NCT03726879), adding atezolizumab (A) to neoadjuvant chemotherapy (CT) and pertuzumab
- Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_380;
Preliminary safety data indicated that the study treatments were overall well tolerated. Together with previous findings showing comparable efficacy and safety profiles and Pts preference of PH FDC SC versus P-IV+H-IV in (neo)adjuvant settings, these results encourage the use of PH FDC SC for dual blockade treatments.
- Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Real-world effectiveness and safety of neratinib in the extended adjuvant treatment of patients with HER2+ early breast cancer (eBC) in the United States Community Oncology Setting (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_362;
Conclusions Based on these US community oncology data, the real-world effectiveness of neratinib in patients with HER2+ HR+ eBC ? 1 year after completing current adjuvant trastuzumab based therapies is consistent with that observed in the ExteNET study with no new safety findings.
- Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) / Roche, Perjeta (pertuzumab) / Roche
Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_361;
P2
Efficacy data are immature but show high IDFS and OS rates at 3 years. For the latest information on IDFS data, please consult the Poster.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
HER2DX in HER2-positive (HER2+) Inflammatory Breast Cancer (IBC): a correlative analysis from a phase II clinical trial (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_280;
P1, P2
Conclusions HER2DX pCR-high designation may be less frequent in HER2+ IBC compared to HER2+ non-IBC. Lower mRNA expression of HER2 amplicon genes, and higher tumor burden at diagnosis, might explain the differences observed in the distribution of HER2DX scores and signatures between HER2+ IBC and non-IBC.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the BiOnHER study (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_279;
Conclusions The 27-gene HER2DX genomic test predicts pCR following neoadjuvant THP in HER2+ BC. Updated data, including D8 HER2DX results, will be presented at the conference.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2 positive (HER2+) early breast cancer (BC) (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_278;
Conclusions HER2 loss was associated with decrease in ERBB2 mRNA levels, was more frequent in tumors switching from HER2E to non-HER2E subtype, and was not associated with EFS. Further validation on large cohorts is warranted.